key: cord-0912538-flqdf8vd
authors: Mitja, O.; Ubals, M.; Corbacho, M.; Alemany, A.; Suner, C.; Tebe, C.; Tobias, A.; Penafiel, J.; Ballana, E.; Perez, C. A.; Admella, P.; Riera-Marti, N.; Laporte, P.; Mitja, J.; Clua, M.; Bertran, L.; Gavilan, S.; Ara, J.; Sarquella, M.; Argimon, J. M.; Cuatrecasas, G.; Canadas, P.; Elizalde-Torrent, A.; Fabregat, R.; Farre, M.; Forcada, A.; Flores-Mateo, G.; Lopez, C.; Muntada, E.; Nadal, N.; Narejos, S.; Gil-Ortega, A. N.; Prat, N.; Puig, J.; Quinones, C.; Ramirez-Viaplana, F.; Reyes-Uruena, J.; Riveira-Munoz, E.; Ruiz, L.; Sanz, S.; Sentis, A.; Sierra, A.; Velasco, C.; Vivanco-Hidalgo, R. M.
title: A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease
date: 2020-07-26
journal: nan
DOI: 10.1101/2020.07.20.20157651
sha: 022cb01d19e152c42e8c7eadeb89601b0e1c5b03
doc_id: 912538
cord_uid: flqdf8vd

Background Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are limited to non-pharmacological interventions. Hydroxychloroquine (HCQ) has been proposed as a postexposure therapy to prevent Coronavirus disease 2019 (Covid-19) but definitive evidence is lacking. Methods We conducted an open-label, cluster-randomized trial including asymptomatic contacts exposed to a PCR-positive Covid-19 case in Catalonia, Spain. Clusters were randomized to receive no specific therapy (control arm) or HCQ 800mg once, followed by 400mg daily for 6 days (intervention arm). The primary outcome was PCR-confirmed symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, either symptomatically compatible or a PCR-positive result regardless of symptoms. Adverse events (AEs) were assessed up to 28 days. Results The analysis included 2,314 healthy contacts of 672 Covid-19 index cases identified between Mar 17 and Apr 28, 2020. A total of 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy. There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% HCQ), but no treatment-related serious AEs were reported. Conclusions Postexposure therapy with HCQ did not prevent SARS-CoV-2 disease and infection in healthy individuals exposed to a PCR-positive case. Our findings do not support HCQ as postexposure prophylaxis for Covid-19.

The primary outcome was the onset of a confirmed Covid-19 episode, defined as symptomatic illness (at 149 least one of the following symptoms: fever, cough, difficulty breathing, myalgia, headache, sore throat, 150 new olfactory and taste disorder(s), or diarrhea) and a positive SARS-CoV-2 RT-PCR test. The primary 151 outcome was assessed in all asymptomatic individuals, irrespective of the PCR result; in a post hoc 152 analysis, we explored the outcome in individuals with positive and negative PCR separately. Time-to-153 event was defined as the number of days from the date of randomization/exposure to the confirmed date 154 of the onset of symptomatic illness. 155

The secondary outcome was the incidence of SARS-CoV-2 infection, defined as either the RT-PCR 156 detection of SARS-CoV-2 in a nasopharyngeal specimen or the presence of any of the aforementioned 157 symptoms compatible with Covid-19. The rationale for this outcome was to encompass definitions of 158

Covid-19 used elsewhere 12,15 and all possible viral dynamics. We, therefore, assumed that if clinical 159 suspicion is high, infection should not be ruled out based on a negative PCR alone-particularly early in 160 the course of infection. 15 Participants who were hospitalized or died and whose hospital/vital records 161 listed Covid-19 as the main diagnosis (including PCR confirmation) were also considered for the primary 162 and secondary outcomes. We also measured serological positivity (IgM/IgG) of contacts at day 14. Safety 163 outcomes included the frequency and severity of adverse events (AE), serious AE (SAE), and AE of 164 special interest (e.g., cardiac) up to 28 days from treatment start. Causality was assessed by an external 165 panel of pharmacovigilance consultants. 166

With an enrollment target of 95 clusters per trial group 16 -15 participants per cluster and intraclass 168 correlation of 1.0-the initial design yielded 90% power to detect a difference of 10% in the incidence, 169 with expected incidence of 15% in the control arm. Owing to the limited information available by March 170 2020 regarding the cluster size and the incidence of Covid-19 after exposure, the protocol prespecified a 171 sample-size re-estimation at the interim analysis. This re-estimation was aimed at maintaining the ability 172 (80% power) to detect a reduction from 6.5% to 3% of the primary outcome, yielding 320 clusters per 173 trial group with 3.5 participants per cluster. 174

The primary efficacy analysis was performed on the intention-to-treat (ITT) population, which included 175 all randomized subjects with complete outcome data. We decided not to impute outcome data to 176 participants with missing measurements because this approach would have biased the incidence of 177 secondary Covid-19 events. Sensitivity analyses were performed with the per-protocol (PP) population in 178 participants who completed the trial according to the protocol. The safety population included all 179 participants who received any trial intervention, including usual care. 180

The cumulative incidence in primary, secondary, and safety outcomes was compared at the individual 181 level using a binomial regression model with robust sandwich standard errors to account for clustering 182 within rings. 17 We defined a generalized linear model with a binomial distribution and a logarithm link 183 function to estimate the relative risk (RR) as a measure of effect. 18 The individual-level variables we 184 adjusted for are age, gender, region, and time of exposure. We did additional pre-specified analyses to 185 assess the consistency of treatment effects in subgroups defined according to the viral load of the contact 186 at baseline, viral load of the index case, place of exposure, time of exposure to the index case. Survival 187 curves by study groups on time-to-event outcomes were compared using a Cox proportional hazards 188 model with a cluster-level frailty term to adjust for clustering. 19 The significance threshold was set at a 189 two-sided alpha value of 0.05, unless otherwise indicated, and all statistical analyses were conducted in R 190 version 3.6.2. 20 191

Between Mar 17 and Apr 28, 2020, we assessed 754 Covid-19 index cases for eligibility; 672 of them 194 were selected for defining the corresponding clusters, which included 4,399 contacts (Fig. 1) 

During the 14-day follow-up, 138 (6.0%) of 2,314 participants experienced a PCR-confirmed, 213

symptomatic Covid-19 episode. The primary outcome was similar in the control arm (6.2%; 74/1,198) 214 and the intervention arm (5.7%; 64/1,116; RR 0.89 [95% CI 0.54-1.46]) ( Table 2 ). The incidence of each 215 of the components of the primary outcome did not differ significantly between groups. 216

Overall, the incidence of confirmed Covid-19 was higher in participants who tested positive in the 217 baseline PCR (Table 2) S4 ). 239

Full adherence for the trial intervention was 97.5% (1,268 of 1,300) in the control arm and 95.1% (1,138 241 of 1,1197) in the intervention arm. In the safety population, 77/1,300 (5.9%) participants in the control 242 arm and 671/1,197 (51.6%) in the intervention arm experienced at least one AE during 14 days of follow-243 up ( Table 3 ). The most frequent treatment-related AEs among participants given HCQ were 244 gastrointestinal (diarrhea, nausea, and abdominal pain) and nervous system disorders (drowsiness, 245 headache, and metallic taste) (Tables S4). Thirty-one SAE were reported, 17 in the control arm and 14 in 246 the intervention arm, none of them related to HCQ (Table S5 ). Six AEs of special interest were observed, 247

including five episodes of self-limited palpitations potentially related to treatment (Table S6) Postexposure prophylaxis with HCQ did not prevent Covid-19 disease or SARS-CoV-2 infection in 252 asymptomatic contacts exposed to a PCR-positive index case. In our cohort, the overall attack rate for the 253 PCR-confirmed symptomatic Covid-19 was 6.0%, excluding subjects that were not enrolled because had 254 symptoms before the baseline assessment. HCQ did not decrease the incidence of confirmed Covid-19 255 disease among contacts (6.2 vs. 5.7%). Our trial tested two possible effects of postexposure therapy: 256 prophylaxis in contacts with negative PCR at baseline, and preemptive therapy in contacts with positive 257 PCR at baseline (i.e., prevent progression of asymptomatic infection to disease). This dual scenario 258 mirrors a real-life setting, where the PCR result of people exposed to a known Covid-19 case is usually 259 not available immediately. Among PCR positive contacts at baseline (12% of subjects), the intervention 260 had no apparent efficacy as early preemptive therapy. Of note a baseline positive PCR result significantly 261 increased the risk of developing Covid-19 in our cohort, but a high proportion of participants with this lab 262 result (79%) did not go on to develop symptomatic disease, thus reinforcing the need to quarantine or to 263 increase testing of contacts even if asymptomatic. Also, of importance to the public health decision-264 making is that high Covid-19 viral load (>10 8 log 10 copies/mL (SD) results in more risk of transmission to 265 contacts. 266

The intervention also did not reduce the transmission of SARS-CoV-2 (17.8% vs. 18.7%) or incidence of 267 seropositivity. Notably, the overlap of positive PCR and positive serology was low, which could be 268 related to both, the reported low rate of seroconversion in asymptomatic contacts 21 or the higher risk of 269 false negative PCR result on the initial stage of infection. 15 Regarding safety, we observed a higher 270 incidence of AE in the treatment group, albeit with low severity. This is an open-label study where the 271 psychological components in the treated group cannot be excluded. Furthermore, the side effects reported 272 were mainly at gastrointestinal level, while only five (0.3%) out of 1,479 events could be considered 273 cardiac, thus not confirming previously published data that raised safety concerns. 22 The safety results 274 need to be interpreted considering the dose used, length of treatment, and the lack of ECG monitoring in 275 the study. 276

The strengths of this study are the use of PCR and viral load titration at baseline, at day 14, and 277 potentially when ill, and the measurement of viral load of the source index case to estimate risk of 278 transmission. In addition, we included elderly persons (e.g. ages >90 years of age) from nursing homes. 279

The study has some limitations. Unlike the common procedure in clinical trials, the informed consent 280 signature took place after cluster-randomization. Nevertheless, allocation was revealed to participants 281 after consent signature, therefore we believe the allocation concealment strategy was appropriate to 282 prevent study participants from choosing to participate or not to participate. Owing to the urgency, the 283 trial could not be masked with a placebo, which affected the rate of AE declared (AEs are not commonly 284 reported in the control, non-placebo group), but it did not affect the attrition numbers in the control arm. 285 However, it is worth mentioning that the laboratory staff who performed PCR tests remained unaware of 286 the allocation of each sample. 287

Despite the promising in-vitro results that placed HCQ among the leading candidates for Covid-19 288 treatment and prophylaxis, 23-25 to date there is no strong argument to suggest that HCQ is effective. We 289 provide high-quality evidence on the lack of efficacy of postexposure prophylaxis therapy with HCQ to 290 prevent Covid-19 disease or SARS-CoV-2 infection. The data presented in this report is particularly 291 Table 1 . Baseline characteristics of study participants (contacts) included in the intention-to-treat 418 population (N=2314 

Early Transmission Dynamics in Wuhan, China

Coronavirus-Infected Pneumonia

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of 333 their close contacts in Shenzhen, China: a retrospective cohort study

Report of the WHO-China Joint Mission on Coronavirus Disease

Preliminary estimation of the basic reproduction

-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase 341 of the outbreak

Strengthening Preparedness for COVID-19 in Cities

Urban Settings

Feasibility of controlling COVID-19 outbreaks by isolation 347 of cases and contacts

World Health Organization. WHO global influenza preparedness plan: The role of WHO and 349 recommendations for national measures before and during pandemics

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Remdesivir and chloroquine effectively inhibit the recently 354 emerged novel coronavirus (2019-nCoV) in vitro

Chloroquine is a potent inhibitor of SARS 356 coronavirus infection and spread

Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome 359

Coronavirus 2 (SARS-CoV-2)

A Randomized Trial of Hydroxychloroquine as 361

Postexposure Prophylaxis for Covid-19

Catalan Ministry of Health. Catalan epidemiological surveillance system

Efficacy and effectiveness of an rVSV-365 vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, 366 open-label, cluster-randomised trial (Ebola Ça Suffit!)

Variation in False-Negative Rate of 368

Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since 369

failure (10 symptomatic at baseline, 2 aged <18years) 97 no PCR measurement at day 14 13 consent withdrawn 45 lost-to-follow-up 22 no PCR available on day 14 7 patient's decision to discontinue